A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Trial details
- Registry ID
- NCT04496349
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLNCT04496349 | Ascentage Pharma Group Inc. | Phase 2 | Recruiting | 2026-05-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |